company background image
TRVI logo

Trevi Therapeutics NasdaqGM:TRVI Stock Report

Last Price

US$4.06

Market Cap

US$311.3m

7D

-4.2%

1Y

192.1%

Updated

23 Dec, 2024

Data

Company Financials +

Trevi Therapeutics, Inc.

NasdaqGM:TRVI Stock Report

Market Cap: US$311.3m

TRVI Stock Overview

A clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. More details

TRVI fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Trevi Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Trevi Therapeutics
Historical stock prices
Current Share PriceUS$4.06
52 Week HighUS$4.68
52 Week LowUS$1.27
Beta0.96
1 Month Change39.52%
3 Month Change28.08%
1 Year Change192.09%
3 Year Change465.70%
5 Year Change8.27%
Change since IPO-48.54%

Recent News & Updates

Recent updates

We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth

Sep 27
We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth

We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth

May 24
We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth

Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans

Jan 27
Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans

Trevi adds 19% on full data set from mid-stage cough study

Sep 19

Trevi Therapeutics: Moving Forward

Sep 11

Is Trevi Therapeutics (NASDAQ:TRVI) Using Too Much Debt?

Mar 23
Is Trevi Therapeutics (NASDAQ:TRVI) Using Too Much Debt?

Trevi has a new development chief

Feb 01

Shareholder Returns

TRVIUS PharmaceuticalsUS Market
7D-4.2%-0.3%-2.7%
1Y192.1%7.9%23.4%

Return vs Industry: TRVI exceeded the US Pharmaceuticals industry which returned 7.9% over the past year.

Return vs Market: TRVI exceeded the US Market which returned 23.4% over the past year.

Price Volatility

Is TRVI's price volatile compared to industry and market?
TRVI volatility
TRVI Average Weekly Movement15.9%
Pharmaceuticals Industry Average Movement10.6%
Market Average Movement6.3%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: TRVI's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: TRVI's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201127Jennifer Goodwww.trevitherapeutics.com

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation.

Trevi Therapeutics, Inc. Fundamentals Summary

How do Trevi Therapeutics's earnings and revenue compare to its market cap?
TRVI fundamental statistics
Market capUS$311.31m
Earnings (TTM)-US$44.32m
Revenue (TTM)n/a

0.0x

P/S Ratio

-7.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TRVI income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$44.32m
Earnings-US$44.32m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.58
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did TRVI perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 02:00
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Trevi Therapeutics, Inc. is covered by 11 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBMO Capital Markets Equity Research
Mayank MamtaniB. Riley Securities, Inc.
Jason KolbertD. Boral Capital LLC.